Slow drip, less pain: new study aims to prevent chemo nerve damage

NCT ID NCT03800693

First seen Nov 06, 2025 · Last updated Jun 18, 2026 · Updated 25 times

Summary

This study tests whether giving the chemotherapy drug oxaliplatin over 6 hours instead of the usual 2 hours can prevent or delay nerve damage in people with gastrointestinal cancers. About 60 participants will be randomly assigned to one of two infusion times. The goal is to see if the longer infusion allows patients to stay on full-dose treatment longer without delays or dose reductions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT DIGESTIVE SYSTEM NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory Saint Joseph's Hospital

    RECRUITING

    Atlanta, Georgia, 30342, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Emory University Hospital Midtown

    RECRUITING

    Atlanta, Georgia, 30308, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.